Antibody Cocktail Treatment For Covid:
Doctors from Sir Ganga Ram Hospital in New Delhi have successfully analysed the monoclonal antibody therapy on two Covid-19 patients. This therapy resulted into fast progression of symptoms within first seven days.
About the therapy:
- Two patients were administered REGCov2 (Casirivimab and Imdevimab). They started to produce resistance against SARS-CoV-2, recovered, and then discharged within 12 hours of administration of doses.
- A healthcare worker with high-grade fever, cough, myalgia, severe weakness, and leucopenia was administered REGCov2 on day six of the disease, according to the press release of the hospital.
- This “antibody cocktail treatment” for coronavirus has the potential to prevent case escalation from mild to severe, which requires hospitalization in 70% of cases.
- This therapy is most suited for “high-risk Covid-19 patients” in the first 10 days of symptom onset and who meet any of the listed criteria like age being 65 years or above.
- Monoclonal antibodies are identical copies of antibody that targets one specific antigen.
- They are made by cloning a unique white blood cell.
- All subsequent antibodies which are derived this way belong to a unique parent cell. Monoclonal antibodies have a monovalent affinity.
- They bind only to the same epitope which is part of an antigen recognized by antibody)